Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 1

Conditions

Melanoma 33Neoplasm Metastasis 3Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Sarcoma 1Recurrence 1Oligodendroglioma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Brain Neoplasms 1Astrocytoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 23fludarabine phosphate 20Cyclophosphamide 18Mycophenolic Acid 16Whole-Body Irradiation 15Cyclosporine 15Busulfan 12Tacrolimus 11Methotrexate 10Antilymphocyte Serum 9Radiotherapy 8Melphalan 8Etoposide 8pembrolizumab 7Methylprednisolone 6Filgrastim 6Sirolimus 4Prednisone 4Nivolumab 4sargramostim 3Vincristine 3Transplantation 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3Amplified Fragment Length Polymorphism Analysis 3mogamulizumab 2merphos 2bempegaldesleukin 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Introns × Dermatologic × Clear all
NCT01622933 2017-08-31

Multiple Antigen-Engineered DC Vaccine for Melanoma

University of Pittsburgh

Phase 1 Completed
35 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡